Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
出版年份 2023 全文链接
标题
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
作者
关键词
-
出版物
Lancet Diabetes & Endocrinology
Volume 11, Issue 9, Pages 644-656
出版商
Elsevier BV
发表日期
2023-07-25
DOI
10.1016/s2213-8587(23)00171-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-term cardiovascular outcomes of COVID-19
- (2022) Yan Xie et al. NATURE MEDICINE
- Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
- (2022) Irene Caruso et al. Metabolites
- To curb research misreporting, replace significance and confidence by compatibility: A Preventive Medicine golden jubilee article
- (2022) Sander Greenland et al. PREVENTIVE MEDICINE
- Long-term neurologic outcomes of COVID-19
- (2022) Evan Xu et al. NATURE MEDICINE
- Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
- (2022) Phyo T. Htoo et al. JAMA Network Open
- Temporal Trends in Incidence Rates of Lower Extremity Amputation and Associated Risk Factors Among Patients Using Veterans Health Administration Services From 2008 to 2018
- (2021) Miao Cai et al. JAMA Network Open
- Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
- (2021) Kamlesh Khunti et al. Cardiovascular Diabetology
- Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium‐Glucose Cotransporter‐2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes
- (2021) Yan Xie et al. Journal of the American Heart Association
- Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
- (2021) Yan Xie et al. JAMA Internal Medicine
- Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review
- (2021) Elliott Bosco et al. BMC Medical Research Methodology
- The comparative cardiovascular and renal effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A Scandinavian cohort study
- (2021) Peter Ueda et al. DIABETES OBESITY & METABOLISM
- Overlap Weighting
- (2020) Laine E. Thomas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
- (2020) Chun-Ting Yang et al. Cardiovascular Diabetology
- Assessing the cost‐effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real‐world evidence
- (2020) Phil McEwan et al. DIABETES OBESITY & METABOLISM
- TEMPORARY REMOVAL: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment
- (2020) Ian H. de Boer et al. KIDNEY INTERNATIONAL
- Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
- (2020) Enrico Longato et al. BMJ Open Diabetes Research & Care
- Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
- (2020) Yan Xie et al. DIABETES CARE
- Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
- (2020) Yan Xie et al. DIABETES CARE
- Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
- (2020) Colette DeJong et al. JAMA Internal Medicine
- Eligibility of patients with type 2 diabetes for sodium‐glucose co‐transporter‐2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry
- (2019) Eric Wittbrodt et al. DIABETES OBESITY & METABOLISM
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area
- (2019) Silvia Canivell et al. Journal of Diabetes Research
- Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
- (2019) Subodh Verma AMERICAN JOURNAL OF CARDIOLOGY
- Propensity score weighting for causal inference with multiple treatments
- (2019) Fan Li et al. Annals of Applied Statistics
- Cardiovascular Effects of New Oral Glucose-Lowering Agents
- (2018) André J. Scheen CIRCULATION RESEARCH
- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER
- (2018) Patrick B. Ryan et al. DIABETES OBESITY & METABOLISM
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus
- (2018) Yan Xie et al. KIDNEY INTERNATIONAL
- Making Neighborhood-Disadvantage Metrics Accessible — The Neighborhood Atlas
- (2018) Amy J.H. Kind et al. NEW ENGLAND JOURNAL OF MEDICINE
- Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects
- (2018) Sebastian Schneeweiss Clinical Epidemiology
- How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational study
- (2018) K.I. Birkeland et al. DIABETES OBESITY & METABOLISM
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
- (2018) Henrik Svanström et al. Lancet Diabetes & Endocrinology
- Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury
- (2017) Yan Xie et al. KIDNEY INTERNATIONAL
- Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2017) Mohsen Naghavi et al. LANCET
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
- (2017) Yan Xie et al. BMJ Open
- Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
- (2017) Jacob A. Udell et al. CIRCULATION
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.
- (2016) Miguel A. Hernán et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD
- (2016) Y. Xie et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Variable selection in general multinomial logit models
- (2015) Gerhard Tutz et al. COMPUTATIONAL STATISTICS & DATA ANALYSIS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes
- (2015) Peter C Austin et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
- (2014) Francisco Kerr Saraiva et al. Cardiovascular Diabetology
- Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data
- (2013) Hansoo Kim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- A tutorial on propensity score estimation for multiple treatments using generalized boosted models
- (2013) Daniel F. McCaffrey et al. STATISTICS IN MEDICINE
- Model selection and parameter estimation of a multinomial logistic regression model
- (2012) Shakhawat Hossain et al. JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION
- Beyond the intention-to-treat in comparative effectiveness research
- (2011) Miguel A Hernán et al. Clinical Trials
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Negative Controls
- (2010) Marc Lipsitch et al. EPIDEMIOLOGY
- High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data
- (2009) Sebastian Schneeweiss et al. EPIDEMIOLOGY
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
- (2009) Peter C. Austin STATISTICS IN MEDICINE
- Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling
- (2007) Joseph V. Terza et al. JOURNAL OF HEALTH ECONOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started